Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

Br J Cancer · 1997 · PMC2223944 · PMID 9231932

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

of borderline significanceP = 0.082so close (0.05 < p ≤ 0.1)

The difference was still of borderline significance (P = 0.082), when excluding the one patient in TOR and three patients in the TAM group with liver metastases.

also in 975 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.